The Jazz Pharmaceuticals PLC (JAZZ) Stock Rating Reaffirmed by Leerink Swann

The Jazz Pharmaceuticals PLC (JAZZ) Stock Rating Reaffirmed by Leerink Swann

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)‘s stock had its “buy” rating reiterated by analysts at Leerink Swann in a research report issued to clients and investors on Wednesday.

A number of other analysts have also weighed in on JAZZ. Deutsche Bank AG restated a “buy” rating and issued a $148.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Thursday. TheStreet lowered shares of Jazz Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a research report on Tuesday, November 8th. Mizuho restated a “neutral” rating and issued a $127.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday. BMO Capital Markets restated an “outperform” rating and issued a $192.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, January 12th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $187.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, January 12th. Four research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Jazz Pharmaceuticals PLC presently has an average rating of “Buy” and an average target price of $178.25.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 124.42 on Wednesday. The firm’s 50 day moving average is $109.71 and its 200 day moving average is $122.56. The company has a market cap of $7.45 billion, a PE ratio of 21.76 and a beta of 1.30. Jazz Pharmaceuticals PLC has a 12 month low of $95.80 and a 12 month high of $160.00.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $2.57 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $2.61 by $0.04. The firm had revenue of $374 million for the quarter, compared to analyst estimates of $389.34 million. Jazz Pharmaceuticals PLC had a return on equity of 30.50% and a net margin of 24.81%. The business’s revenue was up 9.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.52 EPS. On average, equities analysts predict that Jazz Pharmaceuticals PLC will post $9.96 earnings per share for the current year.

In other news, COO Russell J. Cox sold 4,000 shares of the business’s stock in a transaction dated Wednesday, January 18th. The shares were sold at an average price of $128.75, for a total transaction of $515,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Patrick G. Enright sold 677 shares of the business’s stock in a transaction dated Friday, December 2nd. The stock was sold at an average price of $101.80, for a total transaction of $68,918.60. Following the sale, the director now directly owns 1,365 shares of the company’s stock, valued at $138,957. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,277 shares of company stock valued at $650,161. Insiders own 3.90% of the company’s stock.

Large investors have recently bought and sold shares of the company. J.Safra Asset Management Corp acquired a new stake in Jazz Pharmaceuticals PLC during the second quarter valued at approximately $101,000. Tredje AP fonden acquired a new stake in Jazz Pharmaceuticals PLC during the second quarter valued at approximately $102,000. Howard Hughes Medical Institute acquired a new stake in Jazz Pharmaceuticals PLC during the third quarter valued at approximately $112,000. Brave Asset Management Inc increased its stake in Jazz Pharmaceuticals PLC by 540.0% in the third quarter. Brave Asset Management Inc now owns 960 shares of the specialty pharmaceutical company’s stock valued at $117,000 after buying an additional 810 shares during the last quarter. Finally, Commonwealth Bank of Australia increased its stake in Jazz Pharmaceuticals PLC by 12.6% in the second quarter. Commonwealth Bank of Australia now owns 839 shares of the specialty pharmaceutical company’s stock valued at $119,000 after buying an additional 94 shares during the last quarter. 89.21% of the stock is owned by institutional investors.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Related posts

Leave a Comment